Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), a biopharmaceutical company operating a contract development and manufacturing organization (CDMO) and an immunology-focused therapeutic development platform, announced that its wholly owned subsidiary, Scinai Biopharma Services Ltd., has entered into a definitive development and clinical manufacturing agreement with a U.S.-based, Nasdaq-listed biopharmaceutical company. The agreement, which expands an existing customer relationship, includes approximately $5.1 million in committed base service fees, subject to performance and contractual terms. The engagement covers development and clinical manufacturing services for an investigational oncology product, with revenue expected during 2026 and 2027 and stability services extending beyond 2027.
Following the agreement, Scinai’s committed customer orders across its Jerusalem and Yavne operations reached approximately $7.6 million, up 300% from $1.9 million at year-end 2025 and more than double the $3.1 million reported in August 2026. The agreement also presents potential additional clinical manufacturing opportunities with an indicative, uncommitted value of $5.85 million for late 2027 through the first half of 2028, subject to further agreements and development milestones.
This deal underscores the growing traction of Scinai’s CDMO business, which provides development and manufacturing services to biotechnology and pharmaceutical companies through facilities in Jerusalem and Yavne, Israel. For investors, the substantial increase in committed orders signals strong demand for Scinai’s services and could translate into revenue growth in the coming years. The company’s dual focus on CDMO services and immunology therapies, including candidates licensed from the Max Planck Society and PinCell S.r.l., positions it to capture value across the biopharma value chain.
The agreement’s expansion of an existing customer relationship highlights Scinai’s ability to retain and grow accounts, a key metric for CDMO success. The potential additional opportunities, though uncommitted, suggest a pipeline of future work that could further bolster Scinai’s financial performance. As the biopharma industry continues to outsource development and manufacturing to specialized providers, Scinai’s demonstrated capacity to secure sizable contracts may enhance its competitive standing.
For the broader market, this news reflects the ongoing trend of outsourcing in biopharma, particularly for oncology products, which require specialized expertise. Scinai’s success in securing this agreement may encourage other CDMOs to pursue similar deals, potentially intensifying competition. For readers, this development is a reminder of the critical role CDMOs play in bringing new therapies to market, and how companies like Scinai contribute to the innovation ecosystem.
To view the full press release, visit https://ibn.fm/5jaNp. The latest news and updates relating to SCNI are available in the company’s newsroom at https://ibn.fm/SCNI. MissionIR, a specialized communications platform, assists IR firms with syndicated content to enhance visibility. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution, and tailored corporate communications solutions.
